NantKwest Profile

3.09
USD 0.03  0.96%
87%
43%

Exercise or conversion by Patrick SoonShiong of 9257 shares of NantKwest subject to Rule 16b-3

NantKwest insider trading alert for exercise of warrant (right to buy) by Patrick SoonShiong, Chairman and CEO, on July 13, 2018. This event was filed by Nantkwest Inc with SEC on 2018-07-13. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

NantKwest Summary

NantKwest (NK) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 155 people. NantKwest is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with market capitalization of 241.29 M. NantKwest is active under Healthcare sector as part of Biotechnology industry. This company has 78.09 M outstanding shares of which 3.18 M shares are now sold short in the market by investors with about 15.93 days to cover all shorted shares. NK reports about 121.79 M in cash with (54.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.56.
Check NantKwest Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 3.09HorizonTargetOdds Above 3.09
85.80%30 days 3.09 14.02%
Based on normal probability distribution, the odds of NantKwest to move above current price in 30 days from now is about 14.02% (This NantKwest probability density function shows the probability of NantKwest Stock to fall within a particular range of prices over 30 days) .

Top Holders

Selected NantKwest Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

NantKwest Against Markets

Risk Adjusted
Performance Score (0 to 100)
2 
Chance of
Financial Distress (0 to 100%)
6 
Equity ratings for NantKwest are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California. NantKwest operates under Biotechnology classification in USA and traded on NASDAQ. It employs 155 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NantKwest SEC Filings
NantKwest SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameNantKwest
President CEO, Board MemberBarry SimonView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCALIFORNIA U.S.A
Business Address3530 John Hopkins Court
ExchangeBATS Exchange
CIK Number0001326110
CUSIP207371105
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.nantkwest.com
Phone858 633 0300
CurrencyUSD - US Dollar

Did you try this?

Run Financial Widgets Now
   

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Financial Widgets

NantKwest Corporate Directors

Richard Kusserow Independent Director
Michael Blaszyk Independent Director
Frederick Driscoll Independent Director
Please see also Stocks Correlation. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.